Diagnostic value of serum pgRNA detection in HBV-infected patients with different clinical outcomes.
Pregenomic RNA (pgRNA) is a direct transcription product of HBV covalently closed circular DNA (cccDNA) and plays important roles in viral genome amplification and replication. This study was designed to investigate whether serum pgRNA is a strong alternative marker for reflecting HBV cccDNA levels and to analyze the correlation between serum pgRNA, serum HBV DNA and hepatitis B surface antigen (HBsAg). A total of 400 HBV-infected patients who received nucleos(t)ide analogs (NAs) therapy with different clinical outcomes were involved in this research. Case group included asymptomatic hepatitis B virus carrier (ASC), chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC), 100 patients for each group. The results showed that the level of HBV pgRNA had significant difference in these 4 groups. Serum pgRNA levels correlated well with serum HBV DNA levels and HBsAg levels (HBV pgRNA levels vs. HBV DNA levels, r=0.58, P<0.001; HBV pgRNA levels vs. HBsAg levels, r=0.47, P<0.001). In addition, we focused on the 108 HBV-infected patients with HBV DNA <500 IU/ml, it was surprising to find that 17.57% (13/74) of HBV pgRNA can be detected even when HBV DNA level was below 20 IU/ml. In conclusion, HBV pgRNA levels in serum can be a surrogate marker for intrahepatic HBV cccDNA compared with serum HBV DNA and HBsAg. The detection of serum HBV pgRNA levels may provide a reference for clinical monitoring of cccDNA levels and the selection of appropriate timing for discontinuing antiviral therapy, especially when HBV DNA levels are below the detection limit.